当前位置: 首页 > 期刊 > 《世界华人消化杂志》 > 2006年第16期
编号:11123228
多药耐药基因蛋白在贲门癌组织中的表达及其临床价值
http://www.100md.com 史宏灿, 石维平, 束余声, 陆世春, 王 康,
贲门癌;多药耐药;P-糖蛋白;谷胱甘肽S-转移酶;拓朴异构酶-Ⅱ;肺耐药相关蛋白史宏灿,石维平,束余声,陆世春,王康,顾学文,田秀春.多药耐药基因蛋白在贲门癌组织中的表达及其临床意义. 世
第1页

    参见附件(2285KB,5页)。

     史宏灿, 石维平, 束余声, 陆世春, 王康, 扬州大学临床医学院胸心外科 江苏省扬州市 225001

    顾学文, 田秀春,
扬州大学临床医学院病理科 江苏省扬州市 225001

    史宏灿,
2003年第二军医大学博士研究生毕业, 副教授, 副主任医师, 主要从事胸部肿瘤的基础与外科临床研究.

    通讯作者: 史宏灿, 225001, 江苏省扬州市南通西路98号, 扬州大学临床医学院胸心外科. shcan111@yahoo.com.cn

    收稿日期:
2006-03-15 接受日期: 2006-04-06

    Expression of P-glycoprotein, glutathione S-transferase-π, topoisomerase Ⅱ and lung resistance protein in cardiac carcinoma and their clinical significances

    Hong-Can Shi, Wei-Ping Shi, Yu-Cheng Shu, Shi-Chun Lu, Kang Wang, Xue-Wen Gu, Xiu-Chun Tian

    Hong-Can Shi, Wei-Ping Shi, Yu-Sheng Shu, Shi-Chun Lu, Kang Wang, Department of Cardiothoracic Surgery, Medical College of Yangzhou University, Yangzhou 225001, Jiangsu Province, China

    Xue-Wen Gu, Xiu-Chun Tian,
Department of Pathology, Medical College of Yangzhou University, Yangzhou 225001, Jiangsu Province, China

    Correspondence to:
Hong-Can Shi, Department of Cardiothoracic Surgery, Medical College of Yangzhou University, Yangzhou 225001, Jiangsu Province, China. shcan111@yahoo.com.cn

    Received:
2006-03-15 Accepted: 2006-04-06

    Abstract

    AIM:To investigate the expression of multidrug resistant proteins and their clinical significances in cardiac carcinoma tissues.

    METHODS:The expression of P-glycoprotein (P-gp), glutathione S-transferase-p (GST-p), topoisomerase Ⅱ (Topo-Ⅱ) and lung resistance protein (LRP) in 69 patients with cardiac carcinoma were determined by SP immunohistochemistry,and the results were studied in correlation with clinicopathological data.

    RESULTS:The positive rates of P-gp, GST-p, Topo-Ⅱ and LRP expression in cardiac carcinoma (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than those in the normal tissues (0, 30%, 20% and 0, respectively, all P < 0.01). The expression of P-gp was correlated with clinical staging (Ⅰ,Ⅱ vs Ⅲ,Ⅳ: 28.6% vs 58.3%, P < 0.05) and lymphatic metastasis (metastasis vs non-metastasis: 67 ......

您现在查看是摘要介绍页,详见PDF附件(2285KB,5页)